Recursion Pharmaceuticals...

7.38
-0.54 (-6.82%)
At close: Feb 06, 2025, 1:59 PM
undefined%
Bid 7.37
Market Cap 2.83B
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -1.54
PE Ratio (ttm) -4.79
Forward PE n/a
Analyst Buy
Ask 7.38
Volume 43,694,593
Avg. Volume (20D) 15,493,866
Open 8.12
Previous Close 7.92
Day's Range 7.34 - 8.28
52-Week Range 5.60 - 15.74
Beta undefined

About RXRX

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial...

Industry Biotechnology
Sector Healthcare
IPO Date Apr 16, 2021
Employees 500
Stock Exchange NASDAQ
Ticker Symbol RXRX

Analyst Forecast

According to 4 analyst ratings, the average rating for RXRX stock is "Buy." The 12-month stock price forecast is $9, which is an increase of 22.03% from the latest price.

Buy 50.00%
Hold 50.00%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Recursion Pharmaceuticals Inc. is scheduled to release its earnings on Feb 25, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
5 months ago
Recursion Pharmaceuticals shares are trading lower... Unlock content with Pro Subscription
7 months ago
-13.47%
Recursion Pharmaceuticals shares are trading lower after the company announced the pricing of a $200 million public offering of 30,769,230 shares at $6.50 per share.